NCT04981938 is a clinical trial of Lobectomy with pulmonary artery reconstruction in Lung Cancer, Nonsmall Cell, sponsored by Centre Hospitalier Régional Universitaire Montpellier.

Who is sponsoring NCT04981938?

NCT04981938 is sponsored by Centre Hospitalier Régional Universitaire Montpellier.

What drugs are being tested in NCT04981938?

Interventions in NCT04981938: Lobectomy with pulmonary artery reconstruction.

What condition does NCT04981938 study?

NCT04981938 studies Lung Cancer, Nonsmall Cell.

Is NCT04981938 still recruiting?

NCT04981938 is currently completed. Last updated 17 September 2021.

Last reviewed 2021-09-17 · How we verify

NCT04981938

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulmonary Function After Arterial Sleeve Lobectomy

Completed Last updated 17 September 2021

What this trial tests

trial testing Lobectomy with pulmonary artery reconstruction in Lung Cancer, Nonsmall Cell in 81 participants. Completed in 1 September 2021.

Timeline

22 July 2021

Primary endpoint
31 July 2021

1 September 2021

Quick facts

Lead sponsor	Centre Hospitalier Régional Universitaire Montpellier
Status	Completed
Study type	OBSERVATIONAL
Enrollment	81
Start date	22 July 2021
Primary completion	31 July 2021
Estimated completion	1 September 2021
Sites	1 location across France

Drugs / interventions tested

Lobectomy with pulmonary artery reconstruction

Conditions studied

Lung Cancer, Nonsmall Cell — all drugs for Lung Cancer, Nonsmall Cell →

Sponsor

Centre Hospitalier Régional Universitaire Montpellier

Who can join

18 and older, any sex, with Lung Cancer, Nonsmall Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lung cancer is the leading cause of cancer death worldwide. Despite the evolution of medical and multimodal treatments, surgical treatment remains the curative management in the localized cancer. Historically, in central lung tumors, pneumonectomy was the gold standard. Currently, bronchial sleeve lobectomy is recommended as first-line treatment over pneumonectomy when complete resection is possible (Grade 2C). In the case of pulmonary artery invasion, lobectomy with arterial resection and reconstruction is now an accepted option for central localized cancer. Despite surgical challenge, arterial sleeve lobectomy is oncologically comparable with pneumonectomy while avoiding the high morbi-mortality. Indeed, this surgery has shown better results than pneumonectomy in terms of overall survival, post-operative mortality, and quality of life. Initially performed in patients with impaired cardio-pulmonary reserves, this parenchymal sparing procedure can be realised in all patients, when anatomical conditions allow a complete resection. In the literature, no study has yet specifically investigated postoperative respiratory function after arterial sleeve lobectomy. The investigators designed a retrospective monocentric study at the University Hospital of Montpellier on 81 lobectomies with pulmonary artery sleeve resection for lung cancer, from January 2001 to December 2020.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Arterial Sleeve Lobectomy: Does Pulmonary Artery Reconstruction Type Impact Lung Function?
Nguyen A, Solovei L, Marty-Ané C, Bourdin A, et al · · 2023 · PMID 37894338 · DOI 10.3390/cancers15204971

Verify or expand the search:

Other recruiting trials for Lung Cancer, Nonsmall Cell

Currently open trials in the same condition.

NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting
NCT06426511 — ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC · Phase 2 · recruiting
NCT06667154 — Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy · Phase 2 · recruiting
NCT05384873 — Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer · NA · recruiting
NCT05537922 — I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04981938 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Régional Universitaire Montpellier
Last refreshed: 17 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04981938.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing